Cargando…
2789. Cefepime Versus Non-Cefepime/Non-Carbapenem Therapy for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Subgroup Analysis of The Carbapenem-Serratia Multicenter Retrospective Cohort Study
BACKGROUND: Serratia Marcescens causes serious infections. Carbapenems were prescribed due to the bacterium’s ability to develop inducible AmpC-mediated resistance. Recent IDSA guidance recommends ceftriaxone and in high-burden cases, cefepime. Evidence on the role of cefepime in the treatment of Se...
Autores principales: | Mughrabi, Abdallah, Maamari, Julian, Phillips, Timothy, Alabbasi, Afaq, Brooks, Aislinn, Nuriev, Rinat, Zenkin, Lisa, Jaber, Bertrand, Nader, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678629/ http://dx.doi.org/10.1093/ofid/ofad500.2400 |
Ejemplares similares
-
2788. Cefepime or Carbapenem Definitive Therapy Versus Other Antibiotics for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023) -
2787. Carbapenem Versus Non-Carbapenem Based Therapy for Blood Stream Infection Caused by Serratia Marcescens: A Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023) -
141. Evaluating Cefepime And Alternative Beta-lactams For The Treatment Of Serratia marcescens Blood Stream Infections
por: Vicente-Lopez, Natcha, et al.
Publicado: (2022) -
2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
por: Go, James, et al.
Publicado: (2018) -
Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients
por: Lu, Brian, et al.
Publicado: (2023)